{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T05:00:52Z","timestamp":1787029252373,"version":"build-2736575974"},"reference-count":254,"publisher":"MDPI AG","issue":"10","license":[{"start":{"date-parts":[[2020,10,17]],"date-time":"2020-10-17T00:00:00Z","timestamp":1602892800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pathogens"],"abstract":"<jats:p>Ebolaviruses, discovered in 1976, belongs to the Filoviridae family, which also includes Marburg and Lloviu viruses. They are negative-stranded RNA viruses with six known species identified to date. Ebola virus (EBOV) is a member of Zaire ebolavirus species and can cause the Ebola virus disease (EVD), an emerging zoonotic disease that results in homeostatic imbalance and multi-organ failure. There are three EBOV outbreaks documented in the last six years resulting in significant morbidity (&gt;32,000 cases) and mortality (&gt;13,500 deaths). The potential factors contributing to the high infectivity of this virus include multiple entry mechanisms, susceptibility of the host cells, employment of multiple immune evasion mechanisms and rapid person-to-person transmission. EBOV infection leads to cytokine storm, disseminated intravascular coagulation, host T cell apoptosis as well as cell mediated and humoral immune response. In this review, a concise recap of cell types targeted by EBOV and EVD symptoms followed by detailed run-through of host innate and adaptive immune responses, virus-driven regulation and their combined effects contributing to the disease pathogenesis has been presented. At last, the vaccine and drug development initiatives as well as challenges related to the management of infection have been discussed.<\/jats:p>","DOI":"10.3390\/pathogens9100850","type":"journal-article","created":{"date-parts":[[2020,10,17]],"date-time":"2020-10-17T08:14:50Z","timestamp":1602922490000},"page":"850","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":32,"title":["Immunological Perspective for Ebola Virus Infection and Various Treatment Measures Taken to Fight the Disease"],"prefix":"10.3390","volume":"9","author":[{"given":"Sahil","family":"Jain","sequence":"first","affiliation":[{"name":"Department of Biotechnology, Thapar Institute of Engineering &amp; Technology, Patiala 147004, Punjab, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Svetlana F.","family":"Khaiboullina","sequence":"additional","affiliation":[{"name":"Department of Microbiology and Immunology, University of Nevada, Reno, NV 89557, USA"},{"name":"Institute of Fundamental Medicine and Biology, Kazan Federal University, 420008 Kazan, Tatarstan, Russia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6581-9346","authenticated-orcid":false,"given":"Manoj","family":"Baranwal","sequence":"additional","affiliation":[{"name":"Department of Biotechnology, Thapar Institute of Engineering &amp; Technology, Patiala 147004, Punjab, India"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2020,10,17]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/j.mam.2007.09.005","article-title":"Ebolavirus and Marburgvirus: Insight the Filoviridae family","volume":"29","author":"Ascenzi","year":"2008","journal-title":"Mol. Asp. Med."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1038\/s41572-020-0147-3","article-title":"Ebola virus disease","volume":"6","author":"Jacob","year":"2020","journal-title":"Nat. Rev. Dis. Primers"},{"key":"ref_3","first-page":"447","article-title":"Guide to the Correct Use of Filoviral Nomenclature","volume":"411","author":"Kuhn","year":"2017","journal-title":"Curr. Top. Microbiol. Immunol."},{"key":"ref_4","doi-asserted-by":"crossref","unstructured":"Coltart, C.E., Lindsey, B., Ghinai, I., Johnson, A.M., and Heymann, D.L. (2017). The Ebola outbreak, 2013\u20132016: Old lessons for new epidemics. Philos. Trans. R. Soc. Lond. Ser. B Biol. Sci., 372.","DOI":"10.1098\/rstb.2016.0297"},{"key":"ref_5","doi-asserted-by":"crossref","unstructured":"Cantoni, D., Hamlet, A., Michaelis, M., Wass, M.N., and Rossman, J.S. (2016). Risks Posed by Reston, the Forgotten Ebolavirus. mSphere, 1.","DOI":"10.1128\/mSphere.00322-16"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"955","DOI":"10.3201\/eid2505.181666","article-title":"Bombali Virus in Mops condylurus Bat, Kenya","volume":"25","author":"Forbes","year":"2019","journal-title":"Emerg. Infect. Dis."},{"key":"ref_7","unstructured":"(2020, August 12). CDC, Available online: https:\/\/www.cdc.gov\/vhf\/ebola\/about.html."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"1832","DOI":"10.1056\/NEJMra1901594","article-title":"Ebola","volume":"382","author":"Feldmann","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/bs.aivir.2017.12.002","article-title":"Filoviruses: Ecology, Molecular Biology, and Evolution","volume":"100","author":"Emanuel","year":"2018","journal-title":"Adv. Virus Res."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1017\/S0950268806007217","article-title":"Understanding the dynamics of Ebola epidemics","volume":"135","author":"Legrand","year":"2006","journal-title":"Epidemiol. Infect."},{"key":"ref_11","first-page":"bav049","article-title":"An Ebola virus-centered knowledge base","volume":"2015","author":"Kamdar","year":"2015","journal-title":"Database J. Biol. Databases Curation"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1016\/j.amjmed.2015.01.035","article-title":"Ebola Virus Disease: A Perspective for the United States","volume":"128","author":"Madariaga","year":"2015","journal-title":"Am. J. Med."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1016\/j.virusres.2015.09.002","article-title":"Viral bioterrorism: Learning the lesson of Ebola virus in West Africa 2013\u20132015","volume":"210","author":"Cenciarelli","year":"2015","journal-title":"Virus Res."},{"key":"ref_14","first-page":"442","article-title":"Ebola virus disease: A review on epidemiology, symptoms, treatment and pathogenesis","volume":"72","author":"Goeijenbier","year":"2014","journal-title":"Neth. J. Med."},{"key":"ref_15","first-page":"39","article-title":"Ebola haemorrhagic fever virus: Pathogenesis, immune responses, potential prevention","volume":"54","author":"Marcinkiewicz","year":"2014","journal-title":"Folia Med. Crac."},{"key":"ref_16","doi-asserted-by":"crossref","unstructured":"Perdomo-Celis, F., Salvato, M.S., Medina-Moreno, S., and Zapata, J.C. (2019). T-Cell Response to Viral Hemorrhagic Fevers. Vaccines, 7.","DOI":"10.3390\/vaccines7010011"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1016\/j.coviro.2018.01.010","article-title":"Immune barriers of Ebola virus infection","volume":"28","author":"McElroy","year":"2018","journal-title":"Curr. Opin. Virol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"761","DOI":"10.2174\/156652405774962344","article-title":"Ebola and Marburg viruses: Pathogenesis and development of countermeasures","volume":"5","author":"Hensley","year":"2005","journal-title":"Curr. Mol. Med."},{"key":"ref_19","unstructured":"(2020, May 07). STATNEWS. Available online: https:\/\/www.statnews.com\/2017\/12\/08\/ebola-vaccine-development\/."},{"key":"ref_20","unstructured":"(2020, May 07). Pharmaintelligence. Available online: https:\/\/pharmaintelligence.informa.com\/resources\/product-content\/missing-in-action-chinas-best-shot-in-ebola-vaccine-race."},{"key":"ref_21","unstructured":"(2020, May 07). EMA. Available online: https:\/\/www.ema.europa.eu\/en\/news\/first-vaccine-protect-against-ebola."},{"key":"ref_22","unstructured":"(2020, May 07). FDA, Available online: https:\/\/www.fda.gov\/news-events\/press-announcements\/first-fda-approved-vaccine-prevention-ebola-virus-disease-marking-critical-milestone-public-health."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"1250","DOI":"10.1038\/cdd.2015.67","article-title":"Molecular mechanisms of Ebola virus pathogenesis: Focus on cell death","volume":"22","author":"Falasca","year":"2015","journal-title":"Cell Death Differ."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"1501","DOI":"10.3390\/v3081501","article-title":"Intracellular events and cell fate in filovirus infection","volume":"3","author":"Olejnik","year":"2011","journal-title":"Viruses"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1086\/517704","article-title":"Marburg and Ebola hemorrhagic fevers: Does the primary course of infection depend on the accessibility of organ-specific macrophages?","volume":"27","author":"Schnittler","year":"1998","journal-title":"Clin. Infect. Dis. Off. Publ. Infect. Dis. Soc. Am."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"2347","DOI":"10.1016\/S0002-9440(10)63591-2","article-title":"Pathogenesis of Ebola hemorrhagic fever in cynomolgus macaques: Evidence that dendritic cells are early and sustained targets of infection","volume":"163","author":"Geisbert","year":"2003","journal-title":"Am. J. Pathol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"1560","DOI":"10.1016\/j.biocel.2005.02.018","article-title":"Ebola virus: The role of macrophages and dendritic cells in the pathogenesis of Ebola hemorrhagic fever","volume":"37","author":"Bray","year":"2005","journal-title":"Int. J. Biochem. Cell Biol."},{"key":"ref_28","first-page":"141","article-title":"Ebola Virus Disease in Humans: Pathophysiology and Immunity","volume":"411","author":"McElroy","year":"2017","journal-title":"Curr. Top. Microbiol. Immunol."},{"key":"ref_29","doi-asserted-by":"crossref","unstructured":"Saeed, M.F., Kolokoltsov, A.A., Albrecht, T., and Davey, R.A. (2010). Cellular entry of ebola virus involves uptake by a macropinocytosis-like mechanism and subsequent trafficking through early and late endosomes. PLoS Pathog., 6.","DOI":"10.1371\/journal.ppat.1001110"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1084\/jem.20011500","article-title":"Lipid raft microdomains: A gateway for compartmentalized trafficking of Ebola and Marburg viruses","volume":"195","author":"Bavari","year":"2002","journal-title":"J. Exp. Med."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"12090","DOI":"10.1128\/JVI.78.21.12090-12095.2004","article-title":"DC-SIGN and DC-SIGNR interact with the glycoprotein of Marburg virus and the S protein of severe acute respiratory syndrome coronavirus","volume":"78","author":"Marzi","year":"2004","journal-title":"J. Virol."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1006\/viro.2000.0601","article-title":"Downregulation of beta1 integrins by Ebola virus glycoprotein: Implication for virus entry","volume":"278","author":"Takada","year":"2000","journal-title":"Virology"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"2943","DOI":"10.1128\/JVI.78.6.2943-2947.2004","article-title":"Human macrophage C-type lectin specific for galactose and N-acetylgalactosamine promotes filovirus entry","volume":"78","author":"Takada","year":"2004","journal-title":"J. Virol."},{"key":"ref_34","first-page":"323","article-title":"Mechanisms of Filovirus Entry","volume":"411","author":"Davey","year":"2017","journal-title":"Curr. Top. Microbiol. Immunol."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"6841","DOI":"10.1128\/JVI.76.13.6841-6844.2002","article-title":"C-type lectins DC-SIGN and L-SIGN mediate cellular entry by Ebola virus in cis and in trans","volume":"76","author":"Alvarez","year":"2002","journal-title":"J. Virol."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"55750","DOI":"10.18632\/oncotarget.18498","article-title":"The lifecycle of the Ebola virus in host cells","volume":"8","author":"Yu","year":"2017","journal-title":"Oncotarget"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1038\/nrmicro2764","article-title":"A new player in the puzzle of filovirus entry","volume":"10","author":"White","year":"2012","journal-title":"Nat. Rev. Microbiol."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1038\/nature10348","article-title":"Ebola virus entry requires the cholesterol transporter Niemann-Pick C1","volume":"477","author":"Carette","year":"2011","journal-title":"Nature"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"2815","DOI":"10.1128\/JVI.80.6.2815-2822.2006","article-title":"Detection of cell-cell fusion mediated by Ebola virus glycoproteins","volume":"80","author":"Takada","year":"2006","journal-title":"J. Virol."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1038\/ncb2510","article-title":"Genome-wide RNAi screening identifies human proteins with a regulatory function in the early secretory pathway","volume":"14","author":"Simpson","year":"2012","journal-title":"Nat. Cell Biol."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"4174","DOI":"10.1128\/JVI.80.8.4174-4178.2006","article-title":"Role of endosomal cathepsins in entry mediated by the Ebola virus glycoprotein","volume":"80","author":"Schornberg","year":"2006","journal-title":"J. Virol."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"2662","DOI":"10.1073\/pnas.96.6.2662","article-title":"Core structure of the envelope glycoprotein GP2 from Ebola virus at 1.9-A resolution","volume":"96","author":"Malashkevich","year":"1999","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1017\/S1462399404008300","article-title":"Ebola virus: New insights into disease aetiopathology and possible therapeutic interventions","volume":"6","author":"Geisbert","year":"2004","journal-title":"Expert Rev. Mol. Med."},{"key":"ref_44","first-page":"3","article-title":"Ebola Hemorrhagic Fever as a Public Health Emergency of International Concern; a Review Article","volume":"3","author":"Safari","year":"2015","journal-title":"Emergency (Tehraniran)"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"1672","DOI":"10.1053\/j.jvca.2015.08.004","article-title":"Cardiovascular and Pulmonary Impact of the Ebola Virus: A Review of Current Literature and Practices","volume":"29","author":"Heller","year":"2015","journal-title":"J. Cardiothorac. Vasc. Anesth."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"1292","DOI":"10.1016\/S1473-3099(15)00144-9","article-title":"Clinical presentation, biochemical, and haematological parameters and their association with outcome in patients with Ebola virus disease: An observational cohort study","volume":"15","author":"Hunt","year":"2015","journal-title":"Lancet Infect. Dis."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1056\/NEJMoa1504874","article-title":"Clinical Management of Ebola Virus Disease in the United States and Europe","volume":"374","author":"Uyeki","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"9877","DOI":"10.1128\/JVI.01410-14","article-title":"Ebola virus modulates transforming growth factor \u03b2 signaling and cellular markers of mesenchyme-like transition in hepatocytes","volume":"88","author":"Kindrachuk","year":"2014","journal-title":"J. Virol."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1146\/annurev-pathol-020712-164041","article-title":"Pathogenesis of the viral hemorrhagic fevers","volume":"8","author":"Paessler","year":"2013","journal-title":"Annu. Rev. Pathol."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1093\/infdis\/jiu088","article-title":"Ebola hemorrhagic Fever: Novel biomarker correlates of clinical outcome","volume":"210","author":"McElroy","year":"2014","journal-title":"J. Infect. Dis."},{"key":"ref_51","doi-asserted-by":"crossref","unstructured":"Lalle, E., Biava, M., Nicastri, E., Colavita, F., Di Caro, A., Vairo, F., Lanini, S., Castilletti, C., Langer, M., and Zumla, A. (2019). Pulmonary Involvement during the Ebola Virus Disease. Viruses, 11.","DOI":"10.3390\/v11090780"},{"key":"ref_52","first-page":"461","article-title":"Neurological Complications of Ebola Virus Infection","volume":"13","author":"Billioux","year":"2016","journal-title":"Neurother. J. Am. Soc. Exp. Neurother."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1097\/ICU.0000000000000426","article-title":"An update on ocular complications of Ebola virus disease","volume":"28","author":"Shantha","year":"2017","journal-title":"Curr. Opin. Ophthalmol."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"e47","DOI":"10.1093\/cid\/civ420","article-title":"Supportive Care of the First 2 Ebola Virus Disease Patients at the Monrovia Medical Unit","volume":"61","author":"Wong","year":"2015","journal-title":"Clin. Infect. Dis. Off. Publ. Infect. Dis. Soc. Am."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1093\/rheumatology\/kex082","article-title":"Musculoskeletal manifestations of Ebola virus","volume":"57","author":"Poller","year":"2018","journal-title":"Rheumatology"},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"4719","DOI":"10.1073\/pnas.1502619112","article-title":"Human Ebola virus infection results in substantial immune activation","volume":"112","author":"McElroy","year":"2015","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"2797","DOI":"10.4049\/jimmunol.170.6.2797","article-title":"Cutting edge: Impairment of dendritic cells and adaptive immunity by Ebola and Lassa viruses","volume":"170","author":"Mahanty","year":"2003","journal-title":"J. Immunol."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1038\/nature17949","article-title":"Unique human immune signature of Ebola virus disease in Guinea","volume":"533","author":"Ruibal","year":"2016","journal-title":"Nature"},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"1128","DOI":"10.1038\/nm.2447","article-title":"CD8+ cellular immunity mediates rAd5 vaccine protection against Ebola virus infection of nonhuman primates","volume":"17","author":"Sullivan","year":"2011","journal-title":"Nat. Med."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"1893","DOI":"10.1073\/pnas.1209591110","article-title":"Antibodies are necessary for rVSV\/ZEBOV-GP-mediated protection against lethal Ebola virus challenge in nonhuman primates","volume":"110","author":"Marzi","year":"2013","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"E7578","DOI":"10.1073\/pnas.1806200115","article-title":"Analysis of CD8(+) T cell response during the 2013\u20132016 Ebola epidemic in West Africa","volume":"115","author":"Sakabe","year":"2018","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"S508","DOI":"10.1093\/infdis\/jiy352","article-title":"T-Cell Receptor Diversity and the Control of T-Cell Homeostasis Mark Ebola Virus Disease Survival in Humans","volume":"218","author":"Speranza","year":"2018","journal-title":"J. Infect. Dis."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1038\/ni.2035","article-title":"T cell exhaustion","volume":"12","author":"Wherry","year":"2011","journal-title":"Nat. Immunol."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1038\/nri2098","article-title":"How Ebola and Marburg viruses battle the immune system","volume":"7","author":"Mohamadzadeh","year":"2007","journal-title":"Nat. Rev. Immunol."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"1246","DOI":"10.1038\/ni1515","article-title":"Upregulation of CTLA-4 by HIV-specific CD4+ T cells correlates with disease progression and defines a reversible immune dysfunction","volume":"8","author":"Kaufmann","year":"2007","journal-title":"Nat. Immunol."},{"key":"ref_66","first-page":"287","article-title":"Comprehensive Characterization of Cellular Immune Responses Following Ebola Virus Infection","volume":"215","author":"Dahlke","year":"2017","journal-title":"J. Infect. Dis."},{"key":"ref_67","doi-asserted-by":"crossref","unstructured":"Iampietro, M., Younan, P., Nishida, A., Dutta, M., Lubaki, N.M., Santos, R.I., Koup, R.A., Katze, M.G., and Bukreyev, A. (2017). Ebola virus glycoprotein directly triggers T lymphocyte death despite of the lack of infection. PLoS Pathog., 13.","DOI":"10.1371\/journal.ppat.1006397"},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1089\/vim.2004.17.390","article-title":"Depletion of peripheral blood T lymphocytes and NK cells during the course of ebola hemorrhagic Fever in cynomolgus macaques","volume":"17","author":"Reed","year":"2004","journal-title":"Viral Immunol."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"e2164","DOI":"10.1038\/cddis.2016.55","article-title":"Longitudinal characterization of dysfunctional T cell-activation during human acute Ebola infection","volume":"7","author":"Agrati","year":"2016","journal-title":"Cell Death Dis."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1038\/7422","article-title":"Defective humoral responses and extensive intravascular apoptosis are associated with fatal outcome in Ebola virus-infected patients","volume":"5","author":"Baize","year":"1999","journal-title":"Nat. Med."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"102375","DOI":"10.1016\/j.jaut.2019.102375","article-title":"Ebola virus disease: An emerging and re-emerging viral threat","volume":"106","author":"Rojas","year":"2020","journal-title":"J. Autoimmun."},{"key":"ref_72","unstructured":"Basler, C.F., and Palese, P. (2004). Molecular and Cellular Biology. Ebola and Marburg Viruses, Horizon Bioscience."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"4058","DOI":"10.4049\/jimmunol.180.6.4058","article-title":"Functional CD8+ T cell responses in lethal Ebola virus infection","volume":"180","author":"Bradfute","year":"2008","journal-title":"J. Immunol."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1128\/JVI.78.2.958-967.2004","article-title":"Persistent infection with ebola virus under conditions of partial immunity","volume":"78","author":"Gupta","year":"2004","journal-title":"J. Virol."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"11025","DOI":"10.1128\/JVI.75.22.11025-11033.2001","article-title":"Infection and activation of monocytes by Marburg and Ebola viruses","volume":"75","author":"West","year":"2001","journal-title":"J. Virol."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"1618","DOI":"10.1086\/379724","article-title":"Mechanisms underlying coagulation abnormalities in ebola hemorrhagic fever: Overexpression of tissue factor in primate monocytes\/macrophages is a key event","volume":"188","author":"Geisbert","year":"2003","journal-title":"J. Infect. Dis."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/S0165-2478(01)00327-3","article-title":"Proinflammatory response during Ebola virus infection of primate models: Possible involvement of the tumor necrosis factor receptor superfamily","volume":"80","author":"Hensley","year":"2002","journal-title":"Immunol. Lett."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1006\/viro.2001.0836","article-title":"Monocyte-derived human macrophages and peripheral blood mononuclear cells infected with ebola virus secrete MIP-1alpha and TNF-alpha and inhibit poly-IC-induced IFN-alpha in vitro","volume":"284","author":"Gupta","year":"2001","journal-title":"Virology"},{"key":"ref_79","doi-asserted-by":"crossref","unstructured":"Younan, P., Iampietro, M., Nishida, A., Ramanathan, P., Santos, R.I., Dutta, M., Lubaki, N.M., Koup, R.A., Katze, M.G., and Bukreyev, A. (2017). Ebola Virus Binding to Tim-1 on T Lymphocytes Induces a Cytokine Storm. mBio, 8.","DOI":"10.1128\/mBio.00845-17"},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1089\/vim.2014.0091","article-title":"Ebola virus infection induces irregular dendritic cell gene expression","volume":"28","author":"Melanson","year":"2015","journal-title":"Viral Immunol."},{"key":"ref_81","doi-asserted-by":"crossref","unstructured":"Wahl-Jensen, V., Kurz, S., Feldmann, F., Buehler, L.K., Kindrachuk, J., DeFilippis, V., da Silva Correia, J., Fr\u00fch, K., Kuhn, J.H., and Burton, D.R. (2011). Ebola virion attachment and entry into human macrophages profoundly effects early cellular gene expression. PLoS Negl. Trop. Dis., 5.","DOI":"10.1371\/journal.pntd.0001359"},{"key":"ref_82","doi-asserted-by":"crossref","unstructured":"Escudero-Perez, B., Volchkova, V.A., Dolnik, O., Lawrence, P., and Volchkov, V.E. (2014). Shed GP of Ebola virus triggers immune activation and increased vascular permeability. PLoS Pathog., 10.","DOI":"10.1371\/journal.ppat.1004509"},{"key":"ref_83","doi-asserted-by":"crossref","unstructured":"Wauquier, N., Becquart, P., Padilla, C., Baize, S., and Leroy, E.M. (2010). Human fatal zaire ebola virus infection is associated with an aberrant innate immunity and with massive lymphocyte apoptosis. PLoS Negl. Trop. Dis., 4.","DOI":"10.1371\/journal.pntd.0000837"},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1093\/cid\/ciw334","article-title":"Kinetic Analysis of Biomarkers in a Cohort of US Patients with Ebola Virus Disease","volume":"63","author":"McElroy","year":"2016","journal-title":"Clin. Infect. Dis. Off. Publ. Infect. Dis. Soc. Am."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"S188","DOI":"10.1086\/514283","article-title":"Markedly elevated levels of interferon (IFN)-gamma, IFN-alpha, interleukin (IL)-2, IL-10, and tumor necrosis factor-alpha associated with fatal Ebola virus infection","volume":"179","author":"Villinger","year":"1999","journal-title":"J. Infect. Dis."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1046\/j.1365-2249.2002.01800.x","article-title":"Inflammatory responses in Ebola virus-infected patients","volume":"128","author":"Baize","year":"2002","journal-title":"Clin. Exp. Immunol."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"10370","DOI":"10.1128\/JVI.78.19.10370-10377.2004","article-title":"Analysis of human peripheral blood samples from fatal and nonfatal cases of Ebola (Sudan) hemorrhagic fever: Cellular responses, virus load, and nitric oxide levels","volume":"78","author":"Sanchez","year":"2004","journal-title":"J. Virol."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"S357","DOI":"10.1086\/520611","article-title":"Cytokine and chemokine expression in humans infected with Sudan Ebola virus","volume":"196","author":"Hutchinson","year":"2007","journal-title":"J. Infect. Dis."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"3399","DOI":"10.1161\/01.ATV.17.12.3399","article-title":"Effect of human recombinant interleukin-6 and interleukin-8 on monocyte procoagulant activity","volume":"17","author":"Neumann","year":"1997","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/S1016-8478(23)13500-X","article-title":"Fragment E derived from both fibrin and fibrinogen stimulates interleukin-6 production in rat peritoneal macrophages","volume":"9","author":"Lee","year":"1999","journal-title":"Mol. Cells"},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"886","DOI":"10.1038\/78654","article-title":"Identification of the Ebola virus glycoprotein as the main viral determinant of vascular cell cytotoxicity and injury","volume":"6","author":"Yang","year":"2000","journal-title":"Nat. Med."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/j.virol.2003.12.014","article-title":"Ebola virus glycoprotein-mediated anoikis of primary human cardiac microvascular endothelial cells","volume":"321","author":"Ray","year":"2004","journal-title":"Virology"},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"10442","DOI":"10.1128\/JVI.79.16.10442-10450.2005","article-title":"Effects of Ebola virus glycoproteins on endothelial cell activation and barrier function","volume":"79","author":"Afanasieva","year":"2005","journal-title":"J. Virol."},{"key":"ref_94","first-page":"97","article-title":"Pathologic features of filovirus infections in humans","volume":"235","author":"Zaki","year":"1999","journal-title":"Curr. Top. Microbiol. Immunol."},{"key":"ref_95","unstructured":"SR, P. (1978). Pathology of Ebola virus infection. Ebola Virus Haemorrhagic Fever, Elsevier\/North-Holland Biomedical Press."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1016\/S0140-6736(77)92000-1","article-title":"Isolation and partial characterisation of a new virus causing acute haemorrhagic fever in Zaire","volume":"1","author":"Johnson","year":"1977","journal-title":"Lancet"},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"2208","DOI":"10.1128\/jvi.70.4.2208-2214.1996","article-title":"Filovirus-induced endothelial leakage triggered by infected monocytes\/macrophages","volume":"70","author":"Feldmann","year":"1996","journal-title":"J. Virol."},{"key":"ref_98","first-page":"16","article-title":"Recombinant tumor necrosis factor and immune interferon act singly and in combination to reorganize human vascular endothelial cell monolayers","volume":"123","author":"Stolpen","year":"1986","journal-title":"Am. J. Pathol."},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"1977","DOI":"10.1084\/jem.169.6.1977","article-title":"Tumor necrosis factor\/cachectin increases permeability of endothelial cell monolayers by a mechanism involving regulatory G proteins","volume":"169","author":"Brett","year":"1989","journal-title":"J. Exp. Med."},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"4330","DOI":"10.1128\/JVI.78.8.4330-4341.2004","article-title":"Rapid diagnosis of Ebola hemorrhagic fever by reverse transcription-PCR in an outbreak setting and assessment of patient viral load as a predictor of outcome","volume":"78","author":"Towner","year":"2004","journal-title":"J. Virol."},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1016\/j.virusres.2015.12.019","article-title":"Specific neutralizing response in plasma from convalescent patients of Ebola Virus Disease against the West Africa Makona variant of Ebola virus","volume":"213","author":"Luczkowiak","year":"2016","journal-title":"Virus Res."},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"1844","DOI":"10.1128\/CVI.00363-12","article-title":"Profiling the native specific human humoral immune response to Sudan Ebola virus strain Gulu by chemiluminescence enzyme-linked immunosorbent assay","volume":"19","author":"Sobarzo","year":"2012","journal-title":"Clin. Vaccine Immunol."},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"S193","DOI":"10.1086\/520609","article-title":"Laboratory diagnosis of Ebola hemorrhagic fever during an outbreak in Yambio, Sudan, 2004","volume":"196","author":"Onyango","year":"2007","journal-title":"J. Infect. Dis."},{"key":"ref_104","first-page":"293","article-title":"Filovirus Strategies to Escape Antiviral Responses","volume":"411","author":"Olejnik","year":"2017","journal-title":"Curr. Top. Microbiol. Immunol."},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1089\/vim.2014.0066","article-title":"Immune evasion in ebolavirus infections","volume":"28","author":"Audet","year":"2015","journal-title":"Viral Immunol."},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/j.chom.2014.07.008","article-title":"Ebola virus VP24 targets a unique NLS binding site on karyopherin alpha 5 to selectively compete with nuclear import of phosphorylated STAT1","volume":"16","author":"Xu","year":"2014","journal-title":"Cell Host Microbe"},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"S904","DOI":"10.1093\/infdis\/jir323","article-title":"The Ebola virus VP24 protein prevents hnRNP C1\/C2 binding to karyopherin \u03b11 and partially alters its nuclear import","volume":"204","author":"Shabman","year":"2011","journal-title":"J. Infect. Dis."},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1016\/j.virol.2015.03.030","article-title":"Innate immune evasion by filoviruses","volume":"479\u2013480","author":"Basler","year":"2015","journal-title":"Virology"},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/j.virol.2016.11.015","article-title":"Novel activities by ebolavirus and marburgvirus interferon antagonists revealed using a standardized in vitro reporter system","volume":"501","author":"Guito","year":"2017","journal-title":"Virology"},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"S953","DOI":"10.1093\/infdis\/jir325","article-title":"The Ebolavirus VP24 protein blocks phosphorylation of p38 mitogen-activated protein kinase","volume":"204","author":"Halfmann","year":"2011","journal-title":"J. Infect. Dis."},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"3004","DOI":"10.1128\/JVI.02459-09","article-title":"Mutations abrogating VP35 interaction with double-stranded RNA render Ebola virus avirulent in guinea pigs","volume":"84","author":"Prins","year":"2010","journal-title":"J. Virol."},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1038\/nsmb.1765","article-title":"Structural basis for dsRNA recognition and interferon antagonism by Ebola VP35","volume":"17","author":"Leung","year":"2010","journal-title":"Nat. Struct. Mol. Biol."},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/j.chom.2013.06.010","article-title":"Mutual Antagonism between the Ebola Virus VP35 Protein and the RIG-I Activator PACT Determines Infection Outcome","volume":"14","author":"Luthra","year":"2013","journal-title":"Cell Host Microbe"},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"10581","DOI":"10.1128\/JVI.00925-10","article-title":"Basic residues within the ebolavirus VP35 protein are required for its viral polymerase cofactor function","volume":"84","author":"Prins","year":"2010","journal-title":"J. Virol."},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1016\/j.biochi.2007.03.001","article-title":"The dsRNA protein kinase PKR: Virus and cell control","volume":"89","author":"Meurs","year":"2007","journal-title":"Biochimie"},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"8993","DOI":"10.1128\/JVI.00523-09","article-title":"Ebola virus VP35 antagonizes PKR activity through its C-terminal interferon inhibitory domain","volume":"83","author":"Gantke","year":"2009","journal-title":"J. Virol."},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"3069","DOI":"10.1128\/JVI.01875-08","article-title":"Ebola virus protein VP35 impairs the function of interferon regulatory factor-activating kinases IKKepsilon and TBK-1","volume":"83","author":"Prins","year":"2009","journal-title":"J. Virol."},{"key":"ref_118","doi-asserted-by":"crossref","unstructured":"Chang, T.-H., Kubota, T., Matsuoka, M., Jones, S., Bradfute, S.B., Bray, M., and Ozato, K. (2009). Ebola Zaire virus blocks type I interferon production by exploiting the host SUMO modification machinery. PLoS Pathog., 5.","DOI":"10.1371\/journal.ppat.1000493"},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1089\/jir.2009.0076","article-title":"Evasion of interferon responses by Ebola and Marburg viruses","volume":"29","author":"Basler","year":"2009","journal-title":"J. Interferon Cytokine Res. Off. J. Int. Soc. Interferon Cytokine Res."},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"7945","DOI":"10.1128\/JVI.77.14.7945-7956.2003","article-title":"The Ebola virus VP35 protein inhibits activation of interferon regulatory factor 3","volume":"77","author":"Basler","year":"2003","journal-title":"J. Virol."},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"7471","DOI":"10.1128\/JVI.03316-12","article-title":"The Lack of Maturation of Ebola Virus-Infected Dendritic Cells Results from the Cooperative Effect of at Least Two Viral Domains","volume":"87","author":"Lubaki","year":"2013","journal-title":"J. Virol."},{"key":"ref_122","doi-asserted-by":"crossref","unstructured":"Mohan, G.S., Li, W., Ye, L., Compans, R.W., and Yang, C. (2012). Antigenic subversion: A novel mechanism of host immune evasion by Ebola virus. PLoS Pathog., 8.","DOI":"10.1371\/journal.ppat.1003065"},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.virol.2016.12.010","article-title":"Comparison of N- and O-linked glycosylation patterns of ebolavirus glycoproteins","volume":"502","author":"Collar","year":"2017","journal-title":"Virology"},{"key":"ref_124","doi-asserted-by":"crossref","unstructured":"Francica, J.R., Varela-Rohena, A., Medvec, A., Plesa, G., Riley, J.L., and Bates, P. (2010). Steric shielding of surface epitopes and impaired immune recognition induced by the ebola virus glycoprotein. PLoS Pathog., 6.","DOI":"10.1371\/journal.ppat.1001098"},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"S850","DOI":"10.1093\/infdis\/jir378","article-title":"The Ebola virus glycoprotein and HIV-1 Vpu employ different strategies to counteract the antiviral factor tetherin","volume":"204","author":"Banning","year":"2011","journal-title":"J. Infect. Dis."},{"key":"ref_126","doi-asserted-by":"crossref","unstructured":"Cocka, L.J., and Bates, P. (2012). Identification of Alternatively Translated Tetherin Isoforms with Differing Antiviral and Signaling Activities. PLoS Pathog., 8.","DOI":"10.1371\/journal.ppat.1002931"},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"1294","DOI":"10.1016\/S0140-6736(80)92352-1","article-title":"Inactivated vaccine for Ebola virus efficacious in guineapig model","volume":"2","author":"Lupton","year":"1980","journal-title":"Lancet"},{"key":"ref_128","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1006\/viro.1998.9176","article-title":"DNA vaccines expressing either the GP or NP genes of Ebola virus protect mice from lethal challenge","volume":"246","author":"Vanderzanden","year":"1998","journal-title":"Virology"},{"key":"ref_129","doi-asserted-by":"crossref","first-page":"4952","DOI":"10.1128\/JVI.03361-12","article-title":"Venezuelan equine encephalitis virus replicon particle vaccine protects nonhuman primates from intramuscular and aerosol challenge with ebolavirus","volume":"87","author":"Herbert","year":"2013","journal-title":"J. Virol."},{"key":"ref_130","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1006\/viro.1998.9367","article-title":"Marburg virus vaccines based upon alphavirus replicons protect guinea pigs and nonhuman primates","volume":"251","author":"Hevey","year":"1998","journal-title":"Virology"},{"key":"ref_131","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1016\/S0264-410X(00)00113-4","article-title":"Recombinant RNA replicons derived from attenuated Venezuelan equine encephalitis virus protect guinea pigs and mice from Ebola hemorrhagic fever virus","volume":"19","author":"Pushko","year":"2000","journal-title":"Vaccine"},{"key":"ref_132","doi-asserted-by":"crossref","first-page":"S430","DOI":"10.1086\/520583","article-title":"Ebola virus-like particle-based vaccine protects nonhuman primates against lethal Ebola virus challenge","volume":"196","author":"Warfield","year":"2007","journal-title":"J. Infect. Dis."},{"key":"ref_133","doi-asserted-by":"crossref","first-page":"4222","DOI":"10.1128\/JVI.02407-10","article-title":"Recombinant adenovirus serotype 26 (Ad26) and Ad35 vaccine vectors bypass immunity to Ad5 and protect nonhuman primates against ebolavirus challenge","volume":"85","author":"Geisbert","year":"2011","journal-title":"J. Virol."},{"key":"ref_134","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1038\/35046108","article-title":"Development of a preventive vaccine for Ebola virus infection in primates","volume":"408","author":"Sullivan","year":"2000","journal-title":"Nature"},{"key":"ref_135","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1128\/CVI.00431-07","article-title":"Vaccine to confer to nonhuman primates complete protection against multistrain Ebola and Marburg virus infections","volume":"15","author":"Swenson","year":"2008","journal-title":"Clin. Vaccine Immunol."},{"key":"ref_136","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1126\/science.aaa4919","article-title":"Vaccines. An Ebola whole-virus vaccine is protective in nonhuman primates","volume":"348","author":"Marzi","year":"2015","journal-title":"Science"},{"key":"ref_137","doi-asserted-by":"crossref","first-page":"1126","DOI":"10.1038\/nm.3702","article-title":"Chimpanzee adenovirus vaccine generates acute and durable protective immunity against ebolavirus challenge","volume":"20","author":"Stanley","year":"2014","journal-title":"Nat. Med."},{"key":"ref_138","doi-asserted-by":"crossref","first-page":"1991","DOI":"10.1080\/21645515.2015.1039757","article-title":"Codon-optimized filovirus DNA vaccines delivered by intramuscular electroporation protect cynomolgus macaques from lethal Ebola and Marburg virus challenges","volume":"11","author":"Altamura","year":"2015","journal-title":"Hum. Vaccines Immunother."},{"key":"ref_139","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1016\/j.virol.2008.09.030","article-title":"Chimeric human parainfluenza virus bearing the Ebola virus glycoprotein as the sole surface protein is immunogenic and highly protective against Ebola virus challenge","volume":"383","author":"Bukreyev","year":"2009","journal-title":"Virology"},{"key":"ref_140","doi-asserted-by":"crossref","first-page":"2267","DOI":"10.1128\/JVI.80.5.2267-2279.2006","article-title":"A single intranasal inoculation with a paramyxovirus-vectored vaccine protects guinea pigs against a lethal-dose Ebola virus challenge","volume":"80","author":"Bukreyev","year":"2006","journal-title":"J. Virol."},{"key":"ref_141","doi-asserted-by":"crossref","first-page":"21674","DOI":"10.1038\/srep21674","article-title":"Cytomegalovirus-based vaccine expressing Ebola virus glycoprotein protects nonhuman primates from Ebola virus infection","volume":"6","author":"Marzi","year":"2016","journal-title":"Sci. Rep."},{"key":"ref_142","doi-asserted-by":"crossref","unstructured":"Blaney, J.E., Marzi, A., Willet, M., Papaneri, A.B., Wirblich, C., Feldmann, F., Holbrook, M., Jahrling, P., Feldmann, H., and Schnell, M.J. (2013). Antibody quality and protection from lethal Ebola virus challenge in nonhuman primates immunized with rabies virus based bivalent vaccine. PLoS Pathog., 9.","DOI":"10.1371\/journal.ppat.1003389"},{"key":"ref_143","doi-asserted-by":"crossref","first-page":"S414","DOI":"10.1093\/infdis\/jiv251","article-title":"Preclinical Development of Inactivated Rabies Virus-Based Polyvalent Vaccine against Rabies and Filoviruses","volume":"212","author":"Willet","year":"2015","journal-title":"J. Infect. Dis."},{"key":"ref_144","doi-asserted-by":"crossref","first-page":"864","DOI":"10.1038\/s41598-017-19041-y","article-title":"A Single Dose of Modified Vaccinia Ankara expressing Ebola Virus Like Particles Protects Nonhuman Primates from Lethal Ebola Virus Challenge","volume":"8","author":"Domi","year":"2018","journal-title":"Sci. Rep."},{"key":"ref_145","doi-asserted-by":"crossref","first-page":"786","DOI":"10.1038\/nm1258","article-title":"Live attenuated recombinant vaccine protects nonhuman primates against Ebola and Marburg viruses","volume":"11","author":"Jones","year":"2005","journal-title":"Nat. Med."},{"key":"ref_146","doi-asserted-by":"crossref","first-page":"S443","DOI":"10.1093\/infdis\/jiv316","article-title":"Vaccination with a Highly Attenuated Recombinant Vesicular Stomatitis Virus Vector Protects against Challenge with a Lethal Dose of Ebola Virus","volume":"212","author":"Matassov","year":"2015","journal-title":"J. Infect. Dis."},{"key":"ref_147","unstructured":"(2020, May 04). ClinicalTrials, Available online: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02464670."},{"key":"ref_148","unstructured":"(2020, May 05). ClinicalTrials, Available online: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04041570."},{"key":"ref_149","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1080\/21645515.2016.1225637","article-title":"Ebola vaccines in clinical trial: The promising candidates","volume":"13","author":"Wang","year":"2017","journal-title":"Hum. Vaccines Immunother."},{"key":"ref_150","unstructured":"(2020, May 06). ClinicalTrials, Available online: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT00072605."},{"key":"ref_151","doi-asserted-by":"crossref","first-page":"3241","DOI":"10.1172\/JCI81532","article-title":"Aerosolized Ebola vaccine protects primates and elicits lung-resident T cell responses","volume":"125","author":"Meyer","year":"2015","journal-title":"J. Clin. Investig."},{"key":"ref_152","unstructured":"(2020, May 11). ClinicalTrials, Available online: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03462004."},{"key":"ref_153","unstructured":"(2020, May 12). ClinicalTrials, Available online: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02495246."},{"key":"ref_154","doi-asserted-by":"crossref","first-page":"1635","DOI":"10.1056\/NEJMoa1411627","article-title":"A Monovalent Chimpanzee Adenovirus Ebola Vaccine Boosted with MVA","volume":"374","author":"Ewer","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"ref_155","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1016\/S0140-6736(16)32617-4","article-title":"Safety and immunogenicity of a recombinant adenovirus type-5 vector-based Ebola vaccine in healthy adults in Sierra Leone: A single-centre, randomised, double-blind, placebo-controlled, phase 2 trial","volume":"389","author":"Zhu","year":"2017","journal-title":"Lancet (Lond. Engl.)"},{"key":"ref_156","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1016\/S1473-3099(15)00486-7","article-title":"Safety and immunogenicity of a chimpanzee adenovirus-vectored Ebola vaccine in healthy adults: A randomised, double-blind, placebo-controlled, dose-finding, phase 1\/2a study","volume":"16","author":"Audran","year":"2016","journal-title":"Lancet Infect. Dis."},{"key":"ref_157","unstructured":"(2020, May 14). ClinicalTrials, Available online: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02548078."},{"key":"ref_158","unstructured":"(2020, May 15). ClinicalTrials, Available online: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02876328."},{"key":"ref_159","unstructured":"(2020, May 21). ClinicalTrials, Available online: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02344407."},{"key":"ref_160","unstructured":"(2020, August 12). ClinicalTrials, Available online: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04152486."},{"key":"ref_161","unstructured":"(2020, May 08). ClinicalTrials, Available online: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03072030."},{"key":"ref_162","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1080\/21645515.2016.1238535","article-title":"Safety and immunogenicity of GamEvac-Combi, a heterologous VSV- and Ad5-vectored Ebola vaccine: An open phase I\/II trial in healthy adults in Russia","volume":"13","author":"Dolzhikova","year":"2017","journal-title":"Hum. Vaccines Immunother."},{"key":"ref_163","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1016\/S0092-8674(01)00482-2","article-title":"An effective AIDS vaccine based on live attenuated vesicular stomatitis virus recombinants","volume":"106","author":"Rose","year":"2001","journal-title":"Cell"},{"key":"ref_164","doi-asserted-by":"crossref","first-page":"1647","DOI":"10.1056\/NEJMoa1502924","article-title":"Phase 1 trials of rVSV Ebola vaccine in Africa and Europe","volume":"374","author":"Agnandji","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"ref_165","doi-asserted-by":"crossref","first-page":"1156","DOI":"10.1016\/S1473-3099(15)00154-1","article-title":"The effect of dose on the safety and immunogenicity of the VSV Ebola candidate vaccine: A randomised double-blind, placebo-controlled phase 1\/2 trial","volume":"15","author":"Huttner","year":"2015","journal-title":"Lancet Infect. Dis."},{"key":"ref_166","unstructured":"Wagner, R.R. (1996). Rhabdoviridae: The Viruses and Their Replication, Lippincott-Raven."},{"key":"ref_167","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1126\/science.aab3920","article-title":"EBOLA VACCINE. VSV-EBOV rapidly protects macaques against infection with the 2014\/15 Ebola virus outbreak strain","volume":"349","author":"Marzi","year":"2015","journal-title":"Science"},{"key":"ref_168","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1016\/j.cell.2020.03.011","article-title":"A Vaccine against Ebola Virus","volume":"181","year":"2020","journal-title":"Cell"},{"key":"ref_169","unstructured":"(2020, July 14). ERVEBO, Available online: https:\/\/www.fda.gov\/vaccines-blood-biologics\/ervebo."},{"key":"ref_170","doi-asserted-by":"crossref","first-page":"27944","DOI":"10.1038\/srep27944","article-title":"Circulating follicular T helper cells and cytokine profile in humans following vaccination with the rVSV-ZEBOV Ebola vaccine","volume":"6","author":"Farooq","year":"2016","journal-title":"Sci. Rep."},{"key":"ref_171","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1093\/infdis\/jiz070","article-title":"Safety and Immunogenicity of a 2-Dose Heterologous Vaccination Regimen with Ad26.ZEBOV and MVA-BN-Filo Ebola Vaccines: 12-Month Data from a Phase 1 Randomized Clinical Trial in Uganda and Tanzania","volume":"220","author":"Anywaine","year":"2019","journal-title":"J. Infect. Dis."},{"key":"ref_172","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.1073\/pnas.0708057105","article-title":"Generation of biologically contained Ebola viruses","volume":"105","author":"Halfmann","year":"2008","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_173","doi-asserted-by":"crossref","first-page":"3810","DOI":"10.1128\/JVI.00074-09","article-title":"Replication-deficient ebolavirus as a vaccine candidate","volume":"83","author":"Halfmann","year":"2009","journal-title":"J. Virol."},{"key":"ref_174","unstructured":"(2020, August 27). Rabies in Africa: From Its Origins to the Current Fight. Available online: https:\/\/www.pasteur.fr\/en\/rabies-africa-its-origins-current-fight."},{"key":"ref_175","doi-asserted-by":"crossref","first-page":"S342","DOI":"10.1093\/infdis\/jiw231","article-title":"An Inactivated Rabies Virus-Based Ebola Vaccine, FILORAB1, Adjuvanted with Glucopyranosyl Lipid A in Stable Emulsion Confers Complete Protection in Nonhuman Primate Challenge Models","volume":"214","author":"Johnson","year":"2016","journal-title":"J. Infect. Dis."},{"key":"ref_176","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1039\/C5SC03892H","article-title":"Peptide-based synthetic vaccines","volume":"7","author":"Skwarczynski","year":"2016","journal-title":"Chem. Sci."},{"key":"ref_177","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1186\/1743-422X-9-111","article-title":"Prediction and identification of mouse cytotoxic T lymphocyte epitopes in Ebola virus glycoproteins","volume":"9","author":"Wu","year":"2012","journal-title":"Virol. J."},{"key":"ref_178","first-page":"369","article-title":"Computational elucidation of potential antigenic CTL epitopes in Ebola virus","volume":"36","author":"Dikhit","year":"2015","journal-title":"Infect. Genet. Evol. J. Mol. Epidemiol. Evol. Genet. Infect. Dis."},{"key":"ref_179","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1111\/sji.12302","article-title":"Epitope-based peptide vaccine design and target site depiction against Ebola viruses: An immunoinformatics study","volume":"82","author":"Khan","year":"2015","journal-title":"Scand. J. Immunol."},{"key":"ref_180","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.jtbi.2019.01.016","article-title":"Computational analysis in designing T cell epitopes enriched peptides of Ebola glycoprotein exhibiting strong binding interaction with HLA molecules","volume":"465","author":"Jain","year":"2019","journal-title":"J. Theor. Biol."},{"key":"ref_181","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1007\/s00430-019-00584-y","article-title":"Conserved peptide vaccine candidates containing multiple Ebola nucleoprotein epitopes display interactions with diverse HLA molecules","volume":"208","author":"Jain","year":"2019","journal-title":"Med Microbiol. Immunol."},{"key":"ref_182","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1146\/annurev-micro-090817-062414","article-title":"Ebola: Lessons on Vaccine Development","volume":"72","author":"Feldmann","year":"2018","journal-title":"Annu. Rev. Microbiol."},{"key":"ref_183","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1177\/2051013615611017","article-title":"Clinical development of Ebola vaccines","volume":"3","author":"Sridhar","year":"2015","journal-title":"Ther. Adv. Vaccines"},{"key":"ref_184","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/j.virusres.2011.09.005","article-title":"Progress in recombinant DNA-derived vaccines for Lassa virus and filoviruses","volume":"162","author":"Altamura","year":"2011","journal-title":"Virus Res."},{"key":"ref_185","doi-asserted-by":"crossref","unstructured":"Croyle, M.A., Patel, A., Tran, K.N., Gray, M., Zhang, Y., Strong, J.E., Feldmann, H., and Kobinger, G.P. (2008). Nasal delivery of an adenovirus-based vaccine bypasses pre-existing immunity to the vaccine carrier and improves the immune response in mice. PLoS ONE, 3.","DOI":"10.1371\/journal.pone.0003548"},{"key":"ref_186","doi-asserted-by":"crossref","first-page":"221","DOI":"10.2217\/fvl.14.109","article-title":"Therapeutics for postexposure treatment of Ebola virus infection","volume":"10","author":"Jerebtsova","year":"2015","journal-title":"Future Virol."},{"key":"ref_187","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1021\/acsinfecdis.8b00285","article-title":"Contemporary Anti-Ebola Drug Discovery Approaches and Platforms","volume":"5","author":"Hoyer","year":"2019","journal-title":"ACS Infect. Dis."},{"key":"ref_188","doi-asserted-by":"crossref","first-page":"1953","DOI":"10.1016\/S0140-6736(03)15012-X","article-title":"Treatment of Ebola virus infection with a recombinant inhibitor of factor VIIa\/tissue factor: A study in rhesus monkeys","volume":"362","author":"Geisbert","year":"2003","journal-title":"Lancet (Lond. Engl.)"},{"key":"ref_189","unstructured":"(2020, July 16). ARCA biopharma Receives FDA Orphan Drug Designation for rNAPc2 as a Potential Treatment for Ebola. Available online: https:\/\/www.businesswire.com\/news\/home\/20141210005243\/en\/ARCA-biopharma-Receives-FDA-Orphan-Drug-Designation."},{"key":"ref_190","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1016\/j.tim.2014.04.002","article-title":"Post-exposure therapy of filovirus infections","volume":"22","author":"Wong","year":"2014","journal-title":"Trends Microbiol."},{"key":"ref_191","doi-asserted-by":"crossref","first-page":"1896","DOI":"10.1016\/S0140-6736(10)60357-1","article-title":"Postexposure protection of non-human primates against a lethal Ebola virus challenge with RNA interference: A proof-of-concept study","volume":"375","author":"Geisbert","year":"2010","journal-title":"Lancet (Lond. Engl.)"},{"key":"ref_192","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.1001\/jama.2015.2057","article-title":"Emergency Treatment for Exposure to Ebola Virus: The Need to Fast-track Promising Vaccines","volume":"313","author":"Geisbert","year":"2015","journal-title":"JAMA"},{"key":"ref_193","doi-asserted-by":"crossref","unstructured":"Dunning, J., Sahr, F., Rojek, A., Gannon, F., Carson, G., Idriss, B., Massaquoi, T., Gandi, R., Joseph, S., and Osman, H.K. (2016). Experimental Treatment of Ebola Virus Disease with TKM-130803: A Single-Arm Phase 2 Clinical Trial. PLoS Med., 13.","DOI":"10.1371\/journal.pmed.1001997"},{"key":"ref_194","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1038\/nm.2202","article-title":"Advanced antisense therapies for postexposure protection against lethal filovirus infections","volume":"16","author":"Warren","year":"2010","journal-title":"Nat. Med."},{"key":"ref_195","doi-asserted-by":"crossref","first-page":"6639","DOI":"10.1128\/AAC.03442-14","article-title":"Safety and pharmacokinetic profiles of phosphorodiamidate morpholino oligomers with activity against ebola virus and marburg virus: Results of two single-ascending-dose studies","volume":"58","author":"Heald","year":"2014","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_196","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1007\/s40121-015-0079-5","article-title":"Ebola Virus Infection: Overview and Update on Prevention and Treatment","volume":"4","author":"Martinez","year":"2015","journal-title":"Infect. Dis. Ther."},{"key":"ref_197","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1038\/nature13027","article-title":"Protection against filovirus diseases by a novel broad-spectrum nucleoside analogue BCX4430","volume":"508","author":"Warren","year":"2014","journal-title":"Nature"},{"key":"ref_198","doi-asserted-by":"crossref","first-page":"449","DOI":"10.2183\/pjab.93.027","article-title":"Favipiravir (T-705), a broad spectrum inhibitor of viral RNA polymerase","volume":"93","author":"Furuta","year":"2017","journal-title":"Proc. Jpn. Academy. Ser. B Phys. Biol. Sci."},{"key":"ref_199","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/j.antiviral.2014.01.012","article-title":"Post-exposure efficacy of oral T-705 (Favipiravir) against inhalational Ebola virus infection in a mouse model","volume":"104","author":"Smither","year":"2014","journal-title":"Antivir. Res."},{"key":"ref_200","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/j.antiviral.2017.12.021","article-title":"Efficacy of favipiravir (T-705) in nonhuman primates infected with Ebola virus or Marburg virus","volume":"151","author":"Bixler","year":"2018","journal-title":"Antivir. Res."},{"key":"ref_201","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1016\/S1473-3099(14)71047-3","article-title":"Dose regimen of favipiravir for Ebola virus disease","volume":"15","author":"Taburet","year":"2015","journal-title":"Lancet Infect. Dis."},{"key":"ref_202","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1038\/nature17180","article-title":"Therapeutic efficacy of the small molecule GS-5734 against Ebola virus in rhesus monkeys","volume":"531","author":"Warren","year":"2016","journal-title":"Nature"},{"key":"ref_203","unstructured":"(2020, July 16). Ebola Treatments Approved for Compassionate Use in Current Outbreak. Available online: https:\/\/www.who.int\/ebola\/drc-2018\/treatments-approved-for-compassionate-use\/en\/."},{"key":"ref_204","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.coviro.2019.03.001","article-title":"Current status of small molecule drug development for Ebola virus and other filoviruses","volume":"35","author":"Edwards","year":"2019","journal-title":"Curr. Opin. Virol."},{"key":"ref_205","doi-asserted-by":"crossref","unstructured":"Pardo, J., Shukla, A.M., Chamarthi, G., and Gupte, A. (2020). The journey of remdesivir: From Ebola to COVID-19. Drugs Context, 9.","DOI":"10.7573\/dic.2020-4-14"},{"key":"ref_206","doi-asserted-by":"crossref","first-page":"3106","DOI":"10.1128\/JVI.01456-10","article-title":"Identification of a small-molecule entry inhibitor for filoviruses","volume":"85","author":"Basu","year":"2011","journal-title":"J. Virol."},{"key":"ref_207","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.antiviral.2011.10.011","article-title":"Identification of an antioxidant small-molecule with broad-spectrum antiviral activity","volume":"93","author":"Panchal","year":"2012","journal-title":"Antivir. Res."},{"key":"ref_208","doi-asserted-by":"crossref","first-page":"3157","DOI":"10.1073\/pnas.0909587107","article-title":"A broad-spectrum antiviral targeting entry of enveloped viruses","volume":"107","author":"Wolf","year":"2010","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_209","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/j.antiviral.2009.06.001","article-title":"Development of a broad-spectrum antiviral with activity against Ebola virus","volume":"83","author":"Aman","year":"2009","journal-title":"Antivir. Res."},{"key":"ref_210","doi-asserted-by":"crossref","first-page":"2152","DOI":"10.1128\/AAC.01315-09","article-title":"Antiviral activity of a small-molecule inhibitor of filovirus infection","volume":"54","author":"Warren","year":"2010","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_211","first-page":"87","article-title":"FGI-104: A broad-spectrum small molecule inhibitor of viral infection","volume":"1","author":"Kinch","year":"2009","journal-title":"Am. J. Transl. Res."},{"key":"ref_212","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/S0166-3542(00)00066-8","article-title":"Treatment of lethal Ebola virus infection in mice with a single dose of an S-adenosyl-L-homocysteine hydrolase inhibitor","volume":"45","author":"Bray","year":"2000","journal-title":"Antivir. Res."},{"key":"ref_213","doi-asserted-by":"crossref","first-page":"190ra179","DOI":"10.1126\/scitranslmed.3005471","article-title":"FDA-approved selective estrogen receptor modulators inhibit Ebola virus infection","volume":"5","author":"Johansen","year":"2013","journal-title":"Sci. Transl. Med."},{"key":"ref_214","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1038\/nrmicro1707","article-title":"Targeting the glycans of glycoproteins: A novel paradigm for antiviral therapy","volume":"5","author":"Balzarini","year":"2007","journal-title":"Nat. Rev. Microbiol."},{"key":"ref_215","doi-asserted-by":"crossref","unstructured":"Lee, C. (2019). Griffithsin, a Highly Potent Broad-Spectrum Antiviral Lectin from Red Algae: From Discovery to Clinical Application. Mar. Drugs, 17.","DOI":"10.3390\/md17100567"},{"key":"ref_216","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1093\/infdis\/jiq025","article-title":"High-dose mannose-binding lectin therapy for Ebola virus infection","volume":"203","author":"Michelow","year":"2011","journal-title":"J. Infect. Dis."},{"key":"ref_217","unstructured":"(2020, October 03). ClinicalTrials, Available online: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT0231977279."},{"key":"ref_218","doi-asserted-by":"crossref","unstructured":"Sissoko, D., Laouenan, C., Folkesson, E., M\u2019Lebing, A.B., Beavogui, A.H., Baize, S., Camara, A.M., Maes, P., Shepherd, S., and Danel, C. (2016). Correction: Experimental Treatment with Favipiravir for Ebola Virus Disease (the JIKI Trial): A Historically Controlled, Single-Arm Proof-of-Concept Trial in Guinea. PLoS Med., 13.","DOI":"10.1371\/journal.pmed.1002066"},{"key":"ref_219","doi-asserted-by":"crossref","first-page":"8406","DOI":"10.1021\/bi400704d","article-title":"Development of RNA aptamers targeting Ebola virus VP35","volume":"52","author":"Binning","year":"2013","journal-title":"Biochemistry"},{"key":"ref_220","unstructured":"(2020, October 04). ClinicalTrials, Available online: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT01353027."},{"key":"ref_221","unstructured":"(2020, October 02). ClinicalTrials, Available online: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02041715."},{"key":"ref_222","doi-asserted-by":"crossref","first-page":"7294","DOI":"10.1128\/JVI.00591-14","article-title":"Small-molecule probes targeting the viral PPxY-host Nedd4 interface block egress of a broad range of RNA viruses","volume":"88","author":"Han","year":"2014","journal-title":"J. Virol."},{"key":"ref_223","unstructured":"(2020, October 01). ClinicalTrials, Available online: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02818582."},{"key":"ref_224","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1016\/S0140-6736(19)30036-4","article-title":"Safety, tolerability, pharmacokinetics, and immunogenicity of the therapeutic monoclonal antibody mAb114 targeting Ebola virus glycoprotein (VRC 608): An open-label phase 1 study","volume":"393","author":"Gaudinski","year":"2019","journal-title":"Lancet (Lond. Engl.)"},{"key":"ref_225","doi-asserted-by":"crossref","first-page":"199ra113","DOI":"10.1126\/scitranslmed.3006608","article-title":"Therapeutic intervention of Ebola virus infection in rhesus macaques with the MB-003 monoclonal antibody cocktail","volume":"5","author":"Pettitt","year":"2013","journal-title":"Sci. Transl. Med."},{"key":"ref_226","doi-asserted-by":"crossref","first-page":"138ra181","DOI":"10.1126\/scitranslmed.3003876","article-title":"Successful treatment of ebola virus-infected cynomolgus macaques with monoclonal antibodies","volume":"4","author":"Qiu","year":"2012","journal-title":"Sci. Transl. Med."},{"key":"ref_227","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1038\/nature13777","article-title":"Reversion of advanced Ebola virus disease in nonhuman primates with ZMapp","volume":"514","author":"Qiu","year":"2014","journal-title":"Nature"},{"key":"ref_228","doi-asserted-by":"crossref","first-page":"329ra333","DOI":"10.1126\/scitranslmed.aad9875","article-title":"Two-mAb cocktail protects macaques against the Makona variant of Ebola virus","volume":"8","author":"Qiu","year":"2016","journal-title":"Sci. Transl. Med."},{"key":"ref_229","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1128\/CMR.13.4.602","article-title":"Passive immunity in prevention and treatment of infectious diseases","volume":"13","author":"Keller","year":"2000","journal-title":"Clin. Microbiol. Rev."},{"key":"ref_230","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1093\/cid\/civ680","article-title":"The Use of Ebola Convalescent Plasma to Treat Ebola Virus Disease in Resource-Constrained Settings: A Perspective from the Field","volume":"62","author":"Delamou","year":"2016","journal-title":"Clin. Infect. Dis. Off. Publ. Infect. Dis. Soc. Am."},{"key":"ref_231","doi-asserted-by":"crossref","first-page":"S18","DOI":"10.1086\/514298","article-title":"Treatment of Ebola hemorrhagic fever with blood transfusions from convalescent patients. International Scientific and Technical Committee","volume":"179","author":"Mupapa","year":"1999","journal-title":"J. Infect. Dis."},{"key":"ref_232","doi-asserted-by":"crossref","first-page":"435","DOI":"10.2217\/imt-2017-0010","article-title":"The ongoing evolution of antibody-based treatments for Ebola virus infection","volume":"9","author":"Mendoza","year":"2017","journal-title":"Immunotherapy"},{"key":"ref_233","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1016\/S2213-2600(15)00180-0","article-title":"Acute respiratory distress syndrome after convalescent plasma use: Treatment of a patient with Ebola virus disease contracted in Madrid, Spain","volume":"3","author":"Arsuaga","year":"2015","journal-title":"Lancet Respir. Med."},{"key":"ref_234","doi-asserted-by":"crossref","first-page":"1325","DOI":"10.1080\/13543784.2016.1240785","article-title":"Monoclonal antibodies for the treatment of Ebola virus disease","volume":"25","author":"Moekotte","year":"2016","journal-title":"Expert Opin. Investig. Drugs"},{"key":"ref_235","doi-asserted-by":"crossref","unstructured":"Oswald, W.B., Geisbert, T.W., Davis, K.J., Geisbert, J.B., Sullivan, N.J., Jahrling, P.B., Parren, P.W., and Burton, D.R. (2007). Neutralizing antibody fails to impact the course of Ebola virus infection in monkeys. PLoS Pathog., 3.","DOI":"10.1371\/journal.ppat.0030009"},{"key":"ref_236","doi-asserted-by":"crossref","first-page":"1339","DOI":"10.1126\/science.aad5224","article-title":"Protective monotherapy against lethal Ebola virus infection by a potently neutralizing antibody","volume":"351","author":"Corti","year":"2016","journal-title":"Science"},{"key":"ref_237","doi-asserted-by":"crossref","first-page":"1664","DOI":"10.1126\/science.287.5458.1664","article-title":"Epitopes involved in antibody-mediated protection from Ebola virus","volume":"287","author":"Wilson","year":"2000","journal-title":"Science"},{"key":"ref_238","doi-asserted-by":"crossref","first-page":"18030","DOI":"10.1073\/pnas.1213709109","article-title":"Delayed treatment of Ebola virus infection with plant-derived monoclonal antibodies provides protection in rhesus macaques","volume":"109","author":"Olinger","year":"2012","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_239","doi-asserted-by":"crossref","unstructured":"Qiu, X., Fernando, L., Melito, P.L., Audet, J., Feldmann, H., Kobinger, G., Alimonti, J.B., and Jones, S.M. (2012). Ebola GP-specific monoclonal antibodies protect mice and guinea pigs from lethal Ebola virus infection. PLoS Negl. Trop. Dis., 6.","DOI":"10.1371\/journal.pntd.0001575"},{"key":"ref_240","doi-asserted-by":"crossref","first-page":"3365","DOI":"10.1038\/srep03365","article-title":"Sustained protection against Ebola virus infection following treatment of infected nonhuman primates with ZMAb","volume":"3","author":"Qiu","year":"2013","journal-title":"Sci. Rep."},{"key":"ref_241","doi-asserted-by":"crossref","first-page":"207ra143","DOI":"10.1126\/scitranslmed.3006605","article-title":"mAbs and Ad-vectored IFN-\u03b1 therapy rescue Ebola-infected nonhuman primates when administered after the detection of viremia and symptoms","volume":"5","author":"Qiu","year":"2013","journal-title":"Sci. Transl. Med."},{"key":"ref_242","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.coviro.2016.01.006","article-title":"Antibody therapeutics for Ebola virus disease","volume":"17","author":"Zeitlin","year":"2016","journal-title":"Curr. Opin. Virol."},{"key":"ref_243","doi-asserted-by":"crossref","first-page":"2402","DOI":"10.1056\/NEJMoa1409838","article-title":"Clinical care of two patients with Ebola virus disease in the United States","volume":"371","author":"Lyon","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"ref_244","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1016\/j.molmed.2015.12.005","article-title":"Progression of Ebola Therapeutics during the 2014\u20132015 Outbreak","volume":"22","author":"Mendoza","year":"2016","journal-title":"Trends Mol. Med."},{"key":"ref_245","doi-asserted-by":"crossref","unstructured":"Cowled, C., Stewart, C.R., Likic, V.A., Friedl\u00e4nder, M.R., Tachedjian, M., Jenkins, K.A., Tizard, M.L., Cottee, P., Marsh, G.A., and Zhou, P. (2014). Characterisation of novel microRNAs in the Black flying fox (Pteropus alecto) by deep sequencing. BMC Genom., 15.","DOI":"10.1186\/1471-2164-15-682"},{"key":"ref_246","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.1038\/nature06421","article-title":"Toll-like receptor signalling in macrophages links the autophagy pathway to phagocytosis","volume":"450","author":"Sanjuan","year":"2007","journal-title":"Nature"},{"key":"ref_247","doi-asserted-by":"crossref","first-page":"S346","DOI":"10.1093\/infdis\/jiy294","article-title":"Autophagy-Associated Proteins Control Ebola Virus Internalization into Host Cells","volume":"218","author":"Shtanko","year":"2018","journal-title":"J. Infect. Dis."},{"key":"ref_248","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1136\/bmj.2.6086.541","article-title":"A case of Ebola virus infection","volume":"2","author":"Emond","year":"1977","journal-title":"Br. Med. J."},{"key":"ref_249","doi-asserted-by":"crossref","first-page":"3324","DOI":"10.1128\/JVI.01598-12","article-title":"A mutation in the Ebola virus envelope glycoprotein restricts viral entry in a host species- and cell-type-specific manner","volume":"87","author":"Martinez","year":"2013","journal-title":"J. Virol."},{"key":"ref_250","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1038\/ni.1724","article-title":"Cross-presentation of viral and self antigens by skin-derived CD103+ dendritic cells","volume":"10","author":"Bedoui","year":"2009","journal-title":"Nat. Immunol."},{"key":"ref_251","doi-asserted-by":"crossref","first-page":"17124","DOI":"10.1038\/nmicrobiol.2017.124","article-title":"Viral pathogenesis: Unlocking Ebola persistence","volume":"2","author":"Racine","year":"2017","journal-title":"Nat. Microbiol."},{"key":"ref_252","doi-asserted-by":"crossref","first-page":"2687","DOI":"10.1242\/jcs.01114","article-title":"Rab7 is required for the normal progression of the autophagic pathway in mammalian cells","volume":"117","author":"Gutierrez","year":"2004","journal-title":"J. Cell Sci."},{"key":"ref_253","doi-asserted-by":"crossref","first-page":"5722","DOI":"10.1016\/j.vaccine.2014.08.028","article-title":"Immunization with vesicular stomatitis virus vaccine expressing the Ebola glycoprotein provides sustained long-term protection in rodents","volume":"32","author":"Wong","year":"2014","journal-title":"Vaccine"},{"key":"ref_254","doi-asserted-by":"crossref","unstructured":"Ndungo, E., Herbert, A.S., Raaben, M., Obernosterer, G., Biswas, R., Miller, E.H., Wirchnianski, A.S., Carette, J.E., Brummelkamp, T.R., and Whelan, S.P. (2016). A Single Residue in Ebola Virus Receptor NPC1 Influences Cellular Host Range in Reptiles. mSphere, 1.","DOI":"10.1128\/mSphere.00007-16"}],"container-title":["Pathogens"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2076-0817\/9\/10\/850\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T10:23:16Z","timestamp":1760178196000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2076-0817\/9\/10\/850"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,10,17]]},"references-count":254,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2020,10]]}},"alternative-id":["pathogens9100850"],"URL":"https:\/\/doi.org\/10.3390\/pathogens9100850","relation":{},"ISSN":["2076-0817"],"issn-type":[{"value":"2076-0817","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,10,17]]}}}